

VIH/SIDA

Base de Datos Medline. Búsqueda hasta Septiembre 2003, artículos de revisión (review papers).

1. Pantanowitz L, Dezube BJ. Editorial comment: multiple myeloma and HIV infection--causal or casual coincidence? *AIDS Read* 2003; 13(8):386-7.
2. Bruce RD, Altice FL. Editorial comment: why treat three conditions when it is one patient? *AIDS Read* 2003; 13(8):378-9.
3. Douaihy AB, Jou RJ, Gorske T, Salloum IM. Triple diagnosis: dual diagnosis and HIV disease, part 2. *AIDS Read* 2003;13(8):375-82.
4. Laurence J. HIV therapeutics, continued: another HIV protease inhibitor approved. *AIDS Read* 2003; 13(8):355-6.
5. Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. *JAMA* 2003; 290(11):1510-4.
6. Levine AM, Hancock BW, MacPhail P, Ruff P, Ashcroft RE. The treatment of AIDS-related cancers. *Lancet Oncol* 2003; 4(9):576-81.
7. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. *Lancet Oncol* 2003; 4(9):537-47.
8. Phillips AN, Lepri AC, Lampe F, Johnson M, Sabin CA. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. *AIDS* 2003; 17(13):1863-9.
9. Adebayo RA, Oladoyin AM, Irinoye OO. Comprehensive care for people living with HIV/AIDS: issues and problems of social integration in Nigeria. *Niger J Med* 2003; 12(1):12-21.
10. Ferenczy A, Coutlee F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. *CMAJ* 2003; 169(5):431-4.
11. Lesho EP, Gey DC. Managing issues related to anti-retroviral therapy. *Am Fam Physician* 2003; 68(4):675-86.
12. Meanwell NA, Kadow JF. Inhibitors of the entry of HIV into host cells. *Curr Opin Drug Discov Devel* 2003; 6(4):451-61.
13. Murphy RL. Reviving protease inhibitors: new data and more options. *J Acquir Immune Defic Syndr* 2003; 33 Suppl 1:S43-52.
14. Cohen C. First-line treatment in HIV: many paths to success. *J Acquir Immune Defic Syndr* 2003; 33 Suppl 1:S29-38.
15. Powderly WG. Limitations of current HIV therapies: opportunities for improvement. *J Acquir Immune Defic Syndr* 2003; 33 Suppl 1:S7-12.
16. Zell SC, Nielsen S. Clinical correlates to muscle biopsy findings in HIV patients experiencing fatigue: a case series. *J Int Assoc Physicians AIDS Care (Chic Ill)* 2002; 1(3):90-4.
17. Horwath E. Psychiatric and neuropsychiatric manifestations of HIV infection. *J Int Assoc Physicians AIDS Care (Chic Ill)* 2002; 1 Suppl 1:S1-15.
18. Piliero PJ. Early factors in successful anti-HIV treatment. *J Int Assoc Physicians AIDS Care (Chic Ill)* 2003; 2(1):10-20.
19. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. *Clin Infect Dis* 2003; 37(5):613-27.
20. Ernst J. Alternative treatment modalities in human immunodeficiency virus/acquired immune deficiency syndrome. *Clin Infect Dis* 2003; 37 Suppl 2:S150-3.
21. Fawzi W. Micronutrients and human immunodeficiency virus.

1 En colaboración con la Biblioteca Médica Nacional, UNAH (<http://cidbimena.desastres.hn>), y el Comité Consultivo de la Biblioteca Virtual en Salud de Honduras (<http://www.bvs.hn>).

- ciency virus type 1 disease progression among adults and children. *Clin Infect Dis* 2003; 37 Suppl 2:S112-6.
22. Semba RD. Iron-deficiency anemia and the cycle of poverty among human immunodeficiency virus-infected women in the inner city. *Clin Infect Dis* 2003; 37 Suppl 2:S105-11.
23. Hadigan C. Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. *Clin Infect Dis* 2003; 37 Suppl 2:S101-4.
24. Glesby MJ. Bone disorders in human immunodeficiency virus infection. *Clin Infect Dis* 2003; 37 Suppl 2:S91-5.
25. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. *Clin Infect Dis* 2003; 37 Suppl 2:S85-90.
26. Grunfeld C, Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. *Clin Infect Dis* 2003; 37 Suppl 2:S43-6.
27. Gowda RM, Khan IA, Mehta NJ, Gowda MR, Sacchi TJ, Vasavada BC. Cardiac tamponade in patients with human immunodeficiency virus disease. *Angiology* 2003; 54(4):469-74.
28. Piliero PJ, Colagreco JP. Simplified regimens for treating HIV infection and AIDS. *J Am Acad Nurse Pract* 2003; 15(7):305-12.
29. Copenhaver M, Avants SK, Warburton LA, Margolin A. Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment. *J Psychoactive Drugs* 2003; 35(2):209-18.
30. Thompson B. Lazarus Phenomena: an exploratory study of gay men living with HIV. *Soc Work Health Care* 2003; 37(1):87-114.
31. Roland ME, Lo B, Braff J, Stock PG. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. *Arch Intern Med* 2003; 163(15):1773-8.
32. Almeida OP, Jorge Junior J, Scully C. Paracoccidioidomycosis of the mouth: an emerging deep mycosis. *Crit Rev Oral Biol Med* 2003; 14(4):268-74.
33. Lo B, Bayer R. Establishing ethical trials for treatment and prevention of AIDS in developing countries. *BMJ* 2003; 327(7410):337-9.
34. Carr A. Toxicity of antiretroviral therapy and implications for drug development. *Nat Rev Drug Discov* 2003; 2(8):624-34.
35. Diz Dios P, Scully C. Adverse effects of antiretroviral therapy: focus on orofacial effects. *Expert Opin Drug Saf* 2002; 1(4):307-17.
36. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. *Ann Intern Med* 2003; 139(3):214-26.
37. Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. *Biol Psychiatry* 2003; 54(3):307-16.
38. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. *Biol Psychiatry* 2003; 54(3):295-306.
39. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. *AIDS* 2003; 17(12):1717-30.
40. Douaihy AB, Jou RJ, Gorske T, Salloum IM. Triple diagnosis: dual diagnosis and HIV disease, Part 1. *AIDS Read* 2003; 13(7):331-2, 339-41.
41. Ball SC. Patients who want to stop their medications: treatment interruptions in HIV infection. *AIDS Read* 2003; 13(7):317-9, 324, 342.
42. Laurence J. HIV therapeutics: points from the recent literature. *AIDS Read* 2003; 13(7):305, 307.
43. Kramer M, Lynn W, Lightman S. HIV/AIDS and the eye. *Hosp Med* 2003; 64(7):421-4.
44. Filteau S. Infant-feeding strategies to prevent post-natal HIV transmission. *Trans R Soc Trop Med Hyg* 2003; 97(1):25-9.
45. Salama C, Policar M, Venkataraman M. Isolated pulmonary *Mycobacterium avium* complex infection in patients with human immunodeficiency virus infection: case reports and literature review. *Clin Infect Dis* 2003; 37(3):e35-40.
46. Sepulveda C, Habiyaambere V, Amandua J, Borok M, Kikule E, Mudanga B, Ngoma T, Solomon B. Quality care at the end of life in Africa. *BMJ* 2003; 327(7408):209-13.
47. Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. *Clin Liver Dis* 2003; 7(2):475-99.
48. Lafeuillade A, Tardy JC. Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review. *AIDS Rev* 2003;

- 5(2):80-6.
49. Del Rio C. New challenges in HIV care: prevention among HIV-infected patients. *Top HIV Med* 2003; 11(4):140-4.
 50. Kuiken C, Korber B, Shafer RW. HIV sequence databases. *AIDS Rev* 2003; 5(1):52-61.
 51. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. *AIDS Rev* 2003; 5(1):36-43.
 52. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. *AIDS Rev* 2003; 5(1):25-35.
 53. Clotet B, Negredo E. HIV protease inhibitors and dyslipidemia. *AIDS Rev* 2003; 5(1):19-24.
 54. Saksena NK, Potter SJ. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. *AIDS Rev* 2003; 5(1):3-18.
 55. Miro JM, del Rio A, Mestres CA. Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. *Cardiol Clin* 2003; 21(2):167-84, v-vi.
 56. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. *AIDS* 2003; 17 Suppl 1:S162-9.
 57. Miller TL. Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. *AIDS* 2003; 17 Suppl 1:S130-40.
 58. Scevola D, Di Matteo A, Lanzarini P, Uberti F, Scevola S, Bernini V, Spoladore G, Faga A. Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. *AIDS* 2003; 17 Suppl 1:S123-9.
 59. Lipshultz SE, Fisher SD, Lai WW, Miller TL. Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. *AIDS* 2003; 17 Suppl 1:S96-122.
 60. Bruno R, Sacchi P, Filice G. Overview on the incidence and the characteristics of HIV-related opportunistic infections and neoplasms of the heart: impact of highly active antiretroviral therapy. *AIDS* 2003; 17 Suppl 1:S83-7.
 61. Vittecoq D, Escaut L, Chironi G, Teicher E, Monsuez JJ, Andrejak M, Simon A. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. *AIDS* 2003; 17 Suppl 1:S70-6.
 62. Mooser V. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? *AIDS* 2003; 17 Suppl 1:S65-9.
 63. Moroni M, Antinori S. HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era. *AIDS* 2003; 17 Suppl 1:S51-64.
 64. Barbarina G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. *AIDS* 2003; 17 Suppl 1:S46-50.
 65. Currie PF, Boon NA. Immunopathogenesis of HIV-related heart muscle disease: current perspectives. *AIDS* 2003; 17 Suppl 1:S21-8.
 66. Barbaro G. Pathogenesis of HIV-associated heart disease. *AIDS* 2003; 17 Suppl 1:S12-20.
 67. Volberding PA. HIV therapy in 2003: consensus and controversy. *AIDS* 2003; 17 Suppl 1:S4-11.
 68. Brody S, Potterat JJ. Assessing the role of anal intercourse in the epidemiology of AIDS in Africa. *Int J STD AIDS* 2003; 14(7):431-6.
 69. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishmaniasis in HIV infection. *J Postgrad Med* 2003; 49(1):39-49.
 70. Talashek ML, Norr KF, Dancy BL. Building teen power for sexual health. *J Transcult Nurs* 2003; 14(3):207-16.
 71. Marin BV. HIV prevention in the Hispanic community: sex, culture, and empowerment. *J Transcult Nurs* 2003; 14(3):186-92.
 72. Galanti GA. The Hispanic family and male-female relationships: an overview. *J Transcult Nurs* 2003; 14(3):180-5.
 73. Stebbing J, Bower M. What can oncologists learn from HIV? *Lancet Oncol* 2003; 4(7):438-45.
 74. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. *Autoimmun Rev* 2002; 1(6):329-37.
 75. Stoopler ET, Greenberg MS. Update on herpesvirus infections. *Dent Clin North Am* 2003; 47(3):517-32.
 76. Patton LL. HIV disease. *Dent Clin North Am* 2003; 47(3):467-92.
 77. McMichael A. Prospects for an AIDS vaccine. *Clin Med* 2003; 3(3):269-72.
 78. Watson C, Fisher M. A balance of risks for the treatment of the chronically HIV-infected asymptomatic individual. *Clin Med* 2003; 3(3):212-6.
 79. Forster SM. Diagnosing HIV infection. *Clin Med*

- 2003; 3(3):203-5.
80. Faragon JJ, Lesar TS. Update on prescribing errors with HAART. *AIDS Read* 2003; 13(6):268-70, 274-8.
81. Bruisten SM. Genital ulcers in women. *Curr Womens Health Rep* 2003; 3(4):288-98.
82. Thomas J, Doherty SM. HIV infection--a risk factor for osteoporosis. *J Acquir Immune Defic Syndr* 2003; 33(3):281-91.
83. Feller-Kopman D, Ernst A. The role of bronchoalveolar lavage in the immunocompromised host. *Semin Respir Infect* 2003; 18(2):87-94.
84. Narayanswami G, Salzman SH. Bronchoscopy in the human immunodeficiency virus-infected patient. *Semin Respir Infect* 2003; 18(2):80-6.
85. Albrecht MA, Wilkin TJ, Coakley EP, Hammer SM. Advances in antiretroviral therapy. *Top HIV Med* 2003; 11(3):97-127.
86. Havlir DV, Currier JS. Complications of HIV infection and antiretroviral therapy. *Top HIV Med* 2003; 11(3):86-91.
87. Kaur A, Johnson RP. HIV pathogenesis and vaccine development. *Top HIV Med* 2003; 11(3):76-85.
88. Giami A. Sexual health: the emergence, development, and diversity of a concept. *Annu Rev Sex Res* 2002; 13:1-35.
89. Weiss RA. HIV and AIDS: looking ahead. *Nat Med* 2003; 9(7):887-91.
90. Valdiserri RO, Ogden LL, McCray E. Accomplishments in HIV prevention science: implications for stemming the epidemic. *Nat Med* 2003; 9(7):881-6.
91. McMichael AJ, Hanke T. HIV vaccines 1983-2003. *Nat Med* 2003; 9(7):874-80.
92. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. *Nat Med* 2003; 9(7):861-6.
93. Stevenson M. HIV-1 pathogenesis. *Nat Med* 2003; 9(7):853-60.
94. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. *Nat Med* 2003; 9(7):847-52.
95. Beale AJ. AIDS vaccine: new ideas from old approaches. *J R Soc Med* 2003; 96(7):347-8.
96. Garcia Vazquez E, Cedillos RA, Wheeler DA. Clinical and demographic features of HIV infection in El Salvador. *Rev Panam Salud Publica* 2003; 13(5):327-31.
97. Simonian K. The role of herpesviruses in periodontal disease. *J West Soc Periodontol Periodontol Abstr* 2003; 51(1):5-9.
98. Thorner A, Rosenberg E. Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective. *Drugs* 2003; 63(13):1325-37.
99. Newmeyer JA. Patterns and trends of drug use in the San Francisco Bay Area. *J Psychoactive Drugs* 2003; 35 Suppl 1:127-32.
100. Frame PT. HIV disease in primary care. *Prim Care* 2003; 30(1):205-37.
101. Woolley PD. Men who have sex with men. *Practitioner* 2003; 247(1647):514-9.
102. Abu-Rajab K. Key developments in sexual health. *Practitioner* 2003; 247(1647):443-8.
103. Vermund SH, Powderly WG; Infectious Diseases Society of America; HIV Medicine Association of IDSA. Developing a human immunodeficiency virus/acquired immunodeficiency syndrome therapeutic research agenda for resource-limited countries: a consensus statement. *Clin Infect Dis* 2003; 37(Suppl 1):S4-12.
104. Blower S, Volberding P. What can modeling tell us about the threat of antiviral drug resistance? *Curr Opin Infect Dis* 2002; 15(6):609-14.
105. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. *Curr Opin Infect Dis* 2002; 15(6):569-74.
106. Pozniak A. What happened to sexually transmitted disease prevention? *Curr Opin Infect Dis* 2003; 16(1):33-5.
107. Foss AM, Vickerman PT, Heise L, Watts CH. Shifts in condom use following microbicide introduction: should we be concerned? *AIDS* 2003; 17(8):1227-37.
108. Daar ES. Treatment of primary HIV infection. *MedGenMed* 2002; 4(4):15.
109. Bhargava A, Bigombe B. Public policies and the orphans of AIDS in Africa. *BMJ* 2003; 326(7403):1387-9.
110. Pisani E, Garnett GP, Grassly NC, Brown T, Stover J, Hankins C, Walker N, Ghys PD. Back to basics in HIV prevention: focus on exposure. *BMJ* 2003; 326(7403):1384-7.
111. Brugha R. Antiretroviral treatment in developing countries: the peril of neglecting private providers. *BMJ* 2003; 326(7403):1382-4.

112. Papadopoulos-Eleopoulos E, Turner VF, Papadimitriou JM, Alfonso H, Page BA, Causer D, Mhlongo S, Fiala C, Brink A. High rates of HIV seropositivity in Africa--alternative explanation. *Int J STD AIDS* 2003; 14(6):426-7.
113. Kelly JA, Amirkhanian YA. The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. *Int J STD AIDS* 2003; 14(6):361-71.
114. Hicks C, Currier J, Sax P, Sherer R, Wanke C. Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. *AIDS Patient Care STDS* 2003; 17(5):221-33.
115. Maggiolo F, Ripamonti D, Suter F. Once-a-day HAART: dream or reality? *HIV Clin Trials* 2003; 4(3):193-201.
116. Prendergast BD. HIV and cardiovascular medicine. *Heart*. 2003 Jul;89(7):793-800.
117. Johnson D, Cohen S, Bonacini M. Liver disease and HIV. Hepatitis is an ongoing threat. *Adv Nurse Pract* 2003; 11(6):63-6, 68, 70.
118. Grimwade K, Swingle G. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection. *Cochrane Database Syst Rev* 2003; (2):CD003508.
119. Forna F, Gulmezoglu AM. Interventions for treating trichomoniasis in women. *Cochrane Database Syst Rev* 2003; (2):CD000218.
120. Guth AA. Breast cancer and human immunodeficiency virus infection: issues for the 21st century. *J Womens Health (Larchmt)* 2003; 12(3):227-32.
121. Ogundele MO, Coulter JB. HIV transmission through breastfeeding: problems and prevention. *Ann Trop Paediatr* 2003; 23(2):91-106.
122. Papathanasopoulos MA, Hunt GM, Tiemessen CT. Evolution and diversity of HIV-1 in Africa--a review. *Virus Genes* 2003; 26(2):151-63.
123. Lange JM, van Leeuwen R. Antiretroviral therapy and resistance to antiretroviral drugs. *Ethiop Med J* 2002; 40 Suppl 1:51-75.
124. Ali A. Leishmaniasis and HIV/AIDS co-infections: review of common features and management experiences. *Ethiop Med J* 2002; 40 Suppl 1:37-49.
125. Squires KE. Treating HIV infection and AIDS in women. *AIDS Read* 2003; 13(5):228-34, 239-40.
126. Laurence J. Impact of HAART on HIV-linked malignancies. *AIDS Read* 2003; 13(5):202, 205.
127. Prachakul W, Grant JS. Informal caregivers of persons with HIV/AIDS: a review and analysis. *J Assoc Nurses AIDS Care* 2003; 14(3):55-71.
128. Warren M, Philpott A. Expanding safer sex options: introducing the female condom into national programmes. *Reprod Health Matters* 2003; 11(21):130-9.
129. Berer M. Integration of sexual and reproductive health services: a health sector priority. *Reprod Health Matters* 2003; 11(21):6-15.
130. Shetty AK, Maldonado Y. Preventing mother-to-child transmission of human immunodeficiency virus type 1 in resource-poor countries. *Pediatr Infect Dis J* 2003; 22(6):553-5.
131. Greene MD. Older HIV patients face metabolic complications. *Nurse Pract* 2003; 28(6):17-25.
132. Belleza WG, Browne B. Pulmonary considerations in the immunocompromised patient. *Emerg Med Clin North Am* 2003; 21(2):499-531, x-xi.
133. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. *Medicine (Baltimore)* 2003; 82(3):187-202.
134. Zeller V, Nardi AL, Truffot-Pernot C, Sougakoff W, Stankoff B, Katlama C, Bricaire F. Disseminated infection with a mycobacterium related to *Mycobacterium triplex* with central nervous system involvement associated with AIDS. *J Clin Microbiol* 2003; 41(6):2785-7.
135. Villarreal EC. Current and potential therapies for the treatment of herpes-virus infections. *Prog Drug Res* 2003; 60:263-307.
136. Mody GM, Parke FA, Reveille JD. Articular manifestations of human immunodeficiency virus infection. *Best Pract Res Clin Rheumatol* 2003; 17(2):265-87.

SITIOS WEB

1. www.who.int/health-topics/hiv.htm
2. www.who.int/hiv
3. www.who.int/health_topics/hiv_infections/en
4. www.cdc.gov/hiv/dhap.htm
5. www.paho.org/Spanish/AD/DPC/CD/tb-hiv-hon-2003.htm
6. www.paho.org/English/AD/FCH/AI/antiretrovirals_H_P.htm
7. www.paho.org/english/ad/fch/ai/aids.htm
8. www.niaid.nih.gov/aidstherapeutics/news/news.htm

REVISTA MEDICA HONDUREÑA

1. Navarro JJ, Fernández JA. Síndrome de inmunodeficiencia adquirida en pediatría: comunicación de un caso. *Revista Médica Hondureña* 1988; 56(4): 276-8.
2. Grinspan S. Infección por virus de inmunodeficiencia humana (VIH) asociada a transfusión: actualización. *Revista Médica Hondureña* 1988; 56(4): 284-8.
3. Lozano W, Fernández JA. Seroprevalencia y actitudes de riesgo para virus de inmunodeficiencia humana en población de una prisión. *Revista Médica Hondureña* 1989; 57(1): 19-20.
4. Figueroa M. El SIDA en los homosexuales de Honduras. *Revista Médica Hondureña* 1989; 56(3): 194 -8.
5. Fernández J. SIDA y vida: editorial. *Revista Médica Hondureña* 1990; 58(3): 144.
6. Anónimo. SIDA: sus implicaciones psicosociales: editorial. *Revista Médica Hondureña* 1990; 58(4): 203.
7. Figueroa M y Rasheed S. Patología molecular y diagnóstico de enfermedades infecciosas. *Revista Médica Hondureña* 1991; 59(3): 135.
8. Bu Figueroa E, Fernández J, Alvarado T. Características epidemiológicas y clínicas de los primeros 100 casos de SIDA en Honduras. *Revista Médica Hondureña* 1992; 1(1): 9-13.
9. Godoy A, Sabillón F, Lorenzana de Rivera I. *Revista Médica Hondureña* 2001; 69(1) 3-7.
10. Rivera M. Infección por el virus de inmunodeficiencia humana (VIH) en pediatría. *Revista Médica Hondureña* 2002; 72(3): 127-131.
11. Fernández JA. La epidemia de VIH/SIDA en Honduras: discriminación, estigmatización y derechos humanos. *Revista Médica Hondureña* 2003; 71(1): 35-41.

REVISTA HONDURAS PEDIATRICA

1. Godoy C, Villatoro G, Godoy A. Situación epidemiológica de la infección VIH SIDA en los niños de Honduras. *Revista Honduras Pediátrica* 1997; 28(1) 21-23.

REVISTA MEDICA DE POSTGRADO UNAH

1. Mejía León Gómez P, Wilkinson O, Mejía de Calona A. Manifestaciones cutáneas en pacientes con HIV:

trabajo de actualización en el Hospital Escuela, Abril - Septiembre 1997. *Revista . Postgrado* 1998; 3(1): 22-29.

2. Solórzano SC, Godoy C, Villatoro G, Sabillón F, Godoy A, Lorenzana I, Caballero M. VIH en mujeres postparto y transmisión vertical Hospital Escuela 1997. *Postgrado* 1999 4(1) 26-31.
3. Pineda C, Bú Figueroa E. Relación entre las enfermedades oportunistas y conteo de linfocitos CD4 en pacientes con SIDA. *Postgrado* 1999; 4(1) 36-40.
4. Flores L, López Lutz E. Comportamiento clínico y epidemiológico de infecciones oportunistas por hongos en pacientes infectados con VIH del Instituto Nacional del Tórax y Hospital Escuela. *Postgrado* 1999 4(3) 224-231.
5. Andino K, Godoy C. SIDA en pediatría enfermedades oportunistas e infecciones recurrentes. *Rev. Med. Post. UNAH*. 2001; 6(1) 50-54.
6. García R, Guevara J. Asociación de HIV con condilomatosis genital en pacientes embarazadas en el Hospital Materno Infantil durante 1998-1999. *Postgrado* 2001; 6(3) 299-302.
7. Carbajal BH, Bú Figueroa E, Sierra M. Prevalencia de infecciones oportunistas en pacientes VIH positivo asociados al conteo disminuido en células linfocitos CD4+ Hospital Escuela mayo - septiembre 2001. *Postgrado* 2002; 7(1) 10-14.
8. Erazo K, Rivera DM, Soto RJ. Caracterización clínico – epidemiológica de pacientes pediátricos con SIDA atendidos en el Hospital Escuela entre agosto 1999 septiembre 2001. *Postgrado* 2002; 7(1) 15-21.

TESIS PARA OPTAR AL GRADO DE DOCTOR EN MEDICINA

1. Romero Cáceres, Gina Melania; Rivera Hernández; Bessy Argentina; López Yanez, Isaúl. Conocimientos sobre SIDA en población con actitud de riesgo elevado a contraer SIDA que asiste al cesamo Dr, Miguel Paz Barahona de San Pedro Sula. 1992. HN1.1/616.97*R67dr.
2. Godoy Romero, Alejandro. Seroprevalencia de V.I.H; relación con enfermedades de transmisión sexual y algunos parámetros hematológicos. una muestra poblacional de la isla del Tigre, Amapala, Valle. diciembre 1990 a marzo 1991. 1991. HN1.1/616.97*G58.

DOCUMENTOS SIDA EN HONDURAS

1. Thiebaud Alvarenga, Mirna., Umaña, M. Edgardo; González Valle, Anarda.; Tercero Méndez, Delia Mercedes; Samara Kattan, José; Montoya Ernesto. Aprendamos sobre sexualidad. 1997 HN1.1/612.6*T42.
2. Ministerio de Salud Pública. Manual de manejo sintromico de enfermedades de transmisión sexual. 1996 HN1.1/616.95*M66.
3. Bolaños de Llanos, Leda. Situación actual y perspectivas de las enfermedades de transmisión sexual y del VIH/SIDA en Honduras. 1997 HN1.1/616.951*B68.
4. Gascón Brustenga, Joaquín. Informe de la misión identificación de proyecto en relación con el programa de ETS/SIDA en Honduras. 1989 HN1.1/616.951*G24.
5. Fondo de Población de las Naciones Unidas. Prevención y atención del SIDA: una responsabilidad de todos. 1996 HN1.1/616.97*F67.
6. Figueroa de Pacheco, Ana Lucila. Movilización de la Iglesia Cristiana de Honduras en la prevención del VIH/SIDA. 1997HN1.1/616.97*F17mo.
7. Secretaría de Salud. Manual de atención clínica del adulto con VIH/SIDA. 2000.
8. Gerbase , Antonio Carlos. Measurement of HIV/STD priority prevention indicador 4.1 4.2. 1992 HN1.1/616.95* G36.
9. Secretaría de Salud Pública. Propuesta de primer plano a mediano plazo para la reorientación de los procesos de formación y capacitación en sexualidad, ETS/VIH/SIDA a: maestros, escolares, adolescentes y padres de familia en regiones de salud. 1995 HN1.1 616.9507*P96.
10. Euceda F., Rossany M. Influencia de los mensajes de prevención VIH/SIDA, transmitidos en los medios de comunicación masiva en la población de 15 a 49 años del casco urbano de Tegucigalpa. 1997 HN1.1/616.97*A89.
11. Figueroa, Faizury. El SIDA en Honduras. 1993HN1.1/616.97*F17.



Fe de errata

Por un error involuntario en la pagina 103 del Volumen 71 Número 2 de la Revista Medica Hondureña, aparece el Dr. Conrado Rodríguez como especialista en Tisiología. El Dr. Conrado E. Rodríguez Ortiz es especialista en Radiología reconocido como tal en el Colegio Médico de Honduras.

CUADRO DE EGRESADO

DOCTOR (A)	No. COL.	GRADUACIÓN	NACIMIENTO	ESPECIALIDAD
VALLADARES LEMAIRE	024	24/XI/59	Choluteca, Ch; 24/V/33	NEUROCIRUGÍA-NEUROLOGÍA
REYES SOSA*	041	18/XI/59	8/XI/25	MEDICINA GENERAL
DOMINGUEZ RODRIGUEZ*	052	5/XI/60	Marcala; L.P; 24/V/13	MEDICINA GENERAL
SOSA ALVARADO*	055	12/III/60	Comayagüela, F.M. 6/V/32	MEDICINA GENERAL
TALAVERA WESTIN	085	8/IX/60	Amapala, V; 22/X/28	CIRUGIA PLASTICA
INTERIANO TORRES	087	22/X/60	Copán Ruinas; 6/V/32	MEDICINA GENERAL
CARCAMO TERCERO	092	3/V/60	San Marcos de Colón 28/V/28	CARDIOLOGIA
MONCADA AMADOR	119	15/V/59	Tegucigalpa, F.M. 29/VIII/32	
HANDAL HANDAL A.E.	138	11/XI/59	Urraco, Yoro, 14/XII/33	DERMATOLOGIA
MURILLO SELVA h.	180	10/IX/59	Tegucigalpa, F.M., 28/I/30	CIRUGIA TORACICA
GODOY ARTEAGA	185	13/VIII/60	San Juancito, F.M. 18/VII/34	PEDIATRIA-SAL. PUBL.
CARDONA LOPEZ	186	19/VIII/59	Santa Rosa, Copán 14/VI/31	PATOLOGIA
FORTIN MIDENCE	198	21/III/60	Tegucigalpa, F.M. 22/X/34	
MADRID SELAYA*	202	30/I/60	San Pedro Sula; 4/III/33	
RODRIGUEZ ORTEZ	213	14/XII/60	Pespire, Ch; 11/V/34	RADIOLOGÍA
CARDONA RODRIGUEZ	222	17/I/59	Amapala, Valle; 10/II/28	CITOLOGIA EXFOLIATIVA
GUNERA AGUILAR*	226	23/IX/59	Comayagüela, F.M. 3/V/26	SALUD PUBLICA
ZAMBRANA CASTILLO	283	3/XI/59	Danlí, El P. 18/IX/30	GINECOLOGIA-OBSTETRICIA
RIVERA NUÑEZ	284	14/I/59	Guarita, Lemp. 4/IX/31	SALUD PUBLICA
MEJIA DEL CID	298	2/IV/60	La Esperanza, Int; 11/VII/34	OTORRINOLARINGOLOGIA
OVIDIO PADILLA	318	1/XII/59	Minas de Oro, C. 12/IV/30	PEDIATRIA
DE LEON PAZ	330	23/VI/60	Puerto Cortés; 23/VI/23	DERMATOLOGIA
PAZ RIVERA*	352	1959	Concepción N, S.B. 11/VIII/28	DERMATOLOGIA
LANZA SANDOVAL	353	16/VII/60	Tegucigalpa, F.M. 14/X/32	
BUESO ARIAS*	357	21/V/60	Santa Rosa, Copán 28/XII/26	
HANDAL HANDAL J.E.	390	11/XI/59	San Pedro Sula, 30/III/37	MED. INT. PEDIATRIA
SOSA VIDAL	391	30/X/59	9/III/34	GINECOLOGIA-OBSTETRICIA
AYESTAS LOPEZ	393	21/IX/59	25/VI/30	GINECOLOGIA OBSTETRICIA
PINEDA SANTOS*	395	22/X/60	Santa Rosa, Copán 2/IX/32	SALUD PUBLICA
COELLO NUÑEZ*	405	29/X/60	La Venta, F.M. 21/XI/21	FISIATRIA-ORTOPEDIA
VALENZUELA CUERRERO	425	1960	San Pedro Sula, 29/I/29	PEDIATRIA
SAMAYOA MONCADA	445	22/V/59	Comayagüela, F.M. 29/VII/31	GINECOLOGIA-OBSTETRICIA
MAYES HUETE	450	28/VIII/59	Choloma, Cortés, 3/III/21	MEDICINA GENERAL
TOME ABARCA	520	25/VI/60	Amapala, V; 11/VII/33	PEDIATRIA
OQUELI COLINDRES	624	19/IX/59	San Salvador, E.S. 20/U/33	ORTOP.-TRAUMATOLOGIA
GARCIA GUEVARA	406	1959	Alianza, Valle; 30/I/30	PED.-PERINATOLOGIA

* Colega fallecido al momento de elaborar este ensayo.

NOTA: NO LOGRE OBTENER DATOS DE LOS COLEGAS: Dr. Miguel R. Muñoz Mendoza, Dr. José Roberto Oviedo C. Dr. Miguel A. Guerrero Gálvez y Dr. Antonio Sosa Vidal.

OBSERVACIONES. Dentro de estas dos promociones, los doctores Virgilio Cardona López, Carlos Godoy Arteaga, Fernando Tomé Abarca y Enrique Octavio Samayoa Moncada, llegaron a ocupar la Presidencia del Colegio de Honduras. El Dr. Samayoa Moncada, también se desempeñó como Ministro de Salud de 1994 a 1998, en el gobierno del doctor Carlos Roberto Reina Idiáquez.